



**Universiteit
Leiden**
The Netherlands

Genetic repair of a human induced pluripotent cell line from patient with Dutch-type cerebral amyloid angiopathy

Nahon, D.M.; Ganesh, S.; Hil, F.E. van den; Freund, C.; Mummery, C.L.; Orlova, V.V.

Citation

Nahon, D. M., Ganesh, S., Hil, F. E. van den, Freund, C., Mummery, C. L., & Orlova, V. V. (2023). Genetic repair of a human induced pluripotent cell line from patient with Dutch-type cerebral amyloid angiopathy. *Stem Cell Research*, 71. doi:10.1016/j.scr.2023.103180

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3721061>

Note: To cite this publication please use the final published version (if applicable).



Lab Resource: Genetically-Modified Multiple Cell Lines

Genetic repair of a human induced pluripotent cell line from patient with Dutch-type cerebral amyloid angiopathy

Dennis M. Nahon^a, Sravya Ganesh^b, Francijna E. van den Hil^a, Christian Freund^{a,b},
Christine L. Mummery^a, Valeria V. Orlova^{a,*}

^a Department of Anatomy and Embryology, Leiden University Medical Center, Leiden 2333ZA, The Netherlands

^b Leiden University Medical Center hiPSC Hotel, Leiden 2333ZA, The Netherlands

ABSTRACT

Dutch-type cerebral amyloid angiopathy (D-CAA), also known as hereditary cerebral haemorrhage with amyloidosis-Dutch type (HCHWA-D), is an autosomal dominant disorder caused by a G to C transversion in codon 693 of the amyloid precursor protein (APP) that results in a Gln-to-Glu amino acid substitution. CRISPR-Cas9 editing was used for genetic correction of the mutation in a human induced pluripotent stem cell (hiPSC-) line established previously. The isogenic hiPSCs generated showed typical pluripotent stem cell morphology, expressed all markers of undifferentiated state, displayed a normal karyotype and had the capacity to differentiate into the three germ layers.

1. Resource table

Unique stem cell lines identifier	LUMCi005-A-3 (https://hpscereg.eu/cell-line/LUMCi005-A-3) LUMCi005-A-4 (https://hpscereg.eu/cell-line/LUMCi005-A-4)
Alternative names of stem cell lines	Iso1LUMC0074iHCHWAD01 Iso3LUMC0074iHCHWAD01
Institution	Leiden University Medical Center, LUMC
Contact information of distributor	Valeria V. Orlova (v.orlova@lumc.nl) Dennis M. Nahon (d.nahon@lumc.nl) Christian Freund (c.m.a.h.freund@lumc.nl)
Type of cell lines	hiPSCs
Origin	Human
Additional origin info	Age: 56 Sex: Female Ethnicity: Caucasian
Cell Source	Fibroblasts
Method of reprogramming	Sendai virus, OCT3/4, SOX2, KLF4 and MYC
Clonality	Clonal
Evidence of the reprogramming	qRT-PCR
transgene loss (including genomic copy if applicable)	
Cell culture system used	hiPSCs cultured on Vitronectin in mTeSR plus
Type of Genetic Modification	Genetic correction of heterozygous point mutation in the APP gene
Associated disease	Dutch-type cerebral amyloid angiopathy (D-CAA), also known as hereditary cerebral haemorrhage with amyloidosis-Dutch type (HCHWA-D).

(continued on next column)

(continued)

Gene/locus	APP 21q21.3 Corrected Heterozygous APP c.2077C > G; c.2082 T > C; c.2085 G > C
Method of Modification	CRISPR/Cas9
User-customisable nuclease (UCN) delivery method	Electroporation
All double-stranded DNA genetic material molecules introduced into the cells	N/A
Analysis of the nuclease-targeted allele status	Sequencing of the targeted allele
Method of the off-target nuclease activity prediction and surveillance	Targeted PCR/sequencing
Descriptive name of the transgene	N/A
Eukaryotic selective agent	N/A
resistance cassettes (including inducible, gene/cell type-specific)	
Inducible/constitutive expression system details	N/A
Date archived/stock date	27/02/2020
Cell line repository/bank	https://hpscereg.eu/cell-line/LUMCi005-A-3 https://hpscereg.eu/cell-line/LUMCi005-A-4
Ethical approval	NL45478.058.13/P13.080, Medical Ethical Committee (MEC), Leiden University Medical Center (LUMC).
Addgene/public access repository	N/A
recombinant DNA sources' disclaimers (if applicable)	

* Corresponding author.

E-mail address: v.orlova@lumc.nl (V.V. Orlova).

<https://doi.org/10.1016/j.scr.2023.103180>

Received 28 July 2023; Accepted 7 August 2023

Available online 11 August 2023

1873-5061/© 2023 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Table 1
Characterization and validation.

Classification	Test	Result	Data
Morphology	Brightfield microscopy	Normal morphology	Fig. 1 panel A
Phenotype	Qualitative analysis of IF staining	Positive immunostaining markers of undifferentiated state: SSEA4, OCT3/4 & NANOG	Fig. 1 panel D
	Quantitative analysis by FACS	Increased fluorescent signal over negative control of markers of undifferentiated state: SSEA4, OCT3/4 & NANOG	Fig. 1 panel B
Karyotype	G-band Karyotyping 5–10 Mb	Normal karyotype: 46, XX for both lines	Fig. 1 panel E
Genotyping for the desired genomic alteration/allelic status of the gene of interest	PCR across the edited site and sequencing	PCR + Sanger sequencing confirmed presence edited allele (APP c.2077C > G; c.2082 T > C; c.2085 G > C)	Fig. 1 panel C
	Evaluation of the homozygous status of introduced genomic alteration(s)	PCR + Sanger sequencing confirmed presence of edited allele (APP c.2077C > G; c.2082 T > C; c.2085 G > C)	Fig. 1 panel C
	Transgene-specific PCR	N/A	N/A
Verification of the absence of random plasmid integration events	PCR/Southern	N/A	N/A
Parental and modified cell line genetic identity evidence	Microsatellite PCR (mPCR)	Not performed	N/A
	STR analysis	24 sites tested; all sites matched	Submitted in archive with journal
Off-target nuclease activity analysis	PCR across top 5 predicted top likely off-target sites	Demonstration of the lack mutations in predicted off-target sites	Supplementary Fig. S1
Specific pathogen-free status	Mycoplasma	RT-PCR analysis: Negative	Supplementary Table S1
Multilineage differentiation potential	Short-term differentiation in vitro by IF analysis	Positive immunostaining of the three germ layer markers: ectodermal (NES, PAX6), endodermal (FOXA2, GATA4), mesodermal (T, VIM)	Fig. 1F
Donor screening (OPTIONAL)	N/A	N/A	N/A
Genotype additional info (OPTIONAL)	Blood group genotyping	N/A	N/A
	HLA tissue typing	N/A	N/A

2. Resource utility

D-CAA is a neurodegenerative disorder, caused by a heterozygous mutation in exon 17 of the APP gene on chromosome 21 (E22Q; c.2077 G > C) (Levy et al., 1990). The mutation results in accumulation of amyloid beta (A β) inside the cerebral vascular wall. D-CAA patient hiPSC lines and CRISPR-Cas9 corrected isogenically paired hiPSC-lines are a valuable tool for studying the underlying disease mechanisms.

3. Resource details

D-CAA is caused by a point mutation in the APP gene resulting in severe amyloid deposition in the cerebral vascular wall, vascular dementia and recurrent hemorrhagic strokes from the fifth decade of life onwards, significantly reducing life expectancy (Kamp et al., 2014). The heterozygous mutation in the APP gene, results in a Gln-to-Glu amino acid substitution leading to charge alterations in the A β protein (Herzig et al., 2004). The altered A β is less efficiently degraded and cleared over the blood-brain barrier and induces death of cerebrovascular smooth muscle cells, reducing the stability of the vascular wall. Previously generated D-CAA patient hiPSC-lines (Daoutsali et al., 2019) have been useful for modeling certain aspects of the disease (Daoutsali et al., 2023). In the current study, isogenic lines were created to further this research by correcting the mutation in the hiPSC-line generated previously using a Cas9-ribonucleoprotein (RNP) complex, with a mutation-specific single guide RNA (sgRNA) and a single-stranded oligodeoxynucleotide (ssODN) donor template containing the wild-type sequence with two additional silent mutations, one to introduce a AatII restriction site and the other to disrupt the protospacer adjacent motif (PAM) site (Table 2). Two different guide RNAs (gRNAs) were used in separate targeting experiments of the same line, which resulted in an isogenically corrected line with two clones generated using the first sgRNA and the two other clones generated using the other sgRNA. Single-cell derived colonies were screened for repair using the AatII restriction of PCR amplified APP exon 17 region. One clone per sgRNA, hereafter named LUMCi005-A-3 (gRNA1), LUMCi005-A-4 (gRNA2), was selected and characterized (Table 1). Correction of the mutation (c.2077C > G) and incorporation of silent mutations was confirmed by Sanger sequencing (Fig. 1C). The isogenic clones displayed typical stem cell morphology

with high nucleus to cytoplasm ratio (Fig. 1A) and a normal karyotype was confirmed by G-banding (Fig. 1E). The pluripotency status was confirmed by expression and localization of markers of the undifferentiated state: SSEA4, NANOG and OCT3/4, using flow-cytometry (Fig. 1B) and Immunofluorescence staining (Fig. 1D). The differentiation potential of the lines was confirmed by short-term differentiation assay in vitro, with subsequent immunofluorescence staining for markers of the three germ layers; NESTIN and PAX6 (ectoderm), FOXA2 and GATA4 (endoderm), Brachyury (T), CDX2 and Vimentin (mesoderm) (Fig. 1F). Clones were tested negative for mycoplasma (Supplemental Table S1). Finally, the absence of off-target mutations was confirmed by Sanger sequencing of the five most likely off-target sites within coding regions as predicted by CRISPOR (crispor.tefor.net; Fig S1) (Haeussler et al., 2016).

4. Materials and methods

Ethical statement

This study was approved by the LUMC Medical Ethical Committee (MEC) and informed consent was obtained from the HCHWA-D patient (NL45478.058.13/P13.080).

4.1. Cell culture and mutation correction

For generation of the parental hiPSC line LUMCi005-A, see previous publication (Daoutsali et al., 2019). Cells maintained at at 37C and 5% CO2 and were passaged weekly by dissociating using Gentle Cell Dissociation Reagent (Stem Cell Technologies). For genetic repair 1*10⁵ LUMCi005-A cells were electroporated at passage 20 with the Alt-R Cas9-RNP complex and the ssODN (both IDT) using program 6 of the Neon Transfection System (Invitrogen) and subsequently cultured in 2 Synthmax II-SC (Corning)-coated wells of a 12-well plate in TESR-plus with Cloner2 (Stem Cell Technologies). For single cell cloning, 1000 cells were plated onto a Synthmax II-SC-coated 10 cm dish in TESR-plus with Cloner2. After 8–12 days hiPSC colonies were split into VN-coated 2x wells of a 96-well plate in TESR-plus. The region of interest was amplified by PCR using the Terra PCR Direct Polymerase Mix (TaKaRa) from DNA isolated from one well (QuickExtract solution, Lucigen). Successfully edited clones were identified by AatII enzyme (New

Table 2
Reagents details.

Antibodies used for immunocytochemistry/flow-cytometry			
	Antibody	Dilution	Company Cat # and RRID
Markers of the undifferentiated state (FACS)	BV421 Mouse Anti-OCT3/4	1:25 (100 k cells in 80 ul)	BD Biosciences Cat# 565644, RRID:AB_2739320
Markers of the undifferentiated state (FACS)	Mouse Anti-Human NANOG Monoclonal Antibody, PE Conjugated	1:5 (100 k cells in 80 ul)	BD Biosciences Cat# 560483, RRID:AB_1645522
Markers of the undifferentiated state (FACS)	Anti-SSEA-4-FITC antibody	1:25 (100 k cells in 80 ul)	Miltenyi Biotec Cat# 130–098-371, RRID: AB_2653517
Markers of the undifferentiated state (Immunocytochemistry)	Mouse IgG2b anti-OCT3/4	1:100	Santa Cruz Biotechnology Cat# sc-5279 RRID: AB_628051
Markers of the undifferentiated state (Immunocytochemistry)	Mouse IgG1 anti-NANOG	1:150	Santa Cruz Biotechnology Cat# sc-293121 RRID: AB_2665475
Markers of the undifferentiated state (Immunocytochemistry)	Mouse IgG3 anti-SSEA4	1:30	BioLegend Cat# 330402, RRID:AB_1089208
Differentiation markers (Immunocytochemistry)	Nestin-Alexa488	1:200	Technology Cat#33475. RRID:AB_2799037
Differentiation markers (Immunocytochemistry)	PAX6-Alexa647	1:200	Cell Signaling Technology Cat#60433. RRID: AB_2797599
Differentiation markers (Immunocytochemistry)	FOXA2-Alexa555	1:500	Cell Signaling Technology Cat#8186. RRID: AB_10891055
Differentiation markers (Immunocytochemistry)	GATA4-Alexa647	1:200	Cell Signaling Technology Cat#36966. RRID: AB_2799108Cell Signaling
Differentiation markers (Immunocytochemistry)	Brachyury-Alexa488	1:200	Cell signalling Technology Cat#81694. RRID: AB_2799983
Differentiation markers (Immunocytochemistry)	Vimentin-Alexa647	1:200	Cell signalling Technology Cat#5741. RRID: AB_10695459
Secondary antibodies (Immunocytochemistry)	Donkey anti-Mouse IgG (H + L) Highly cross-adsorbed Secondary, Alexa Fluor 488	1:500	Molecular Probes Cat# A-21206, RRID: AB_2535792
Secondary antibodies (Immunocytochemistry)	Donkey anti-Goat Mouse IgG (H + L) Highly cross-adsorbed Secondary, Alexa Fluor 647	1:500	Thermo Fisher Scientific Cat# A-11031, RRID: AB_144696
Secondary antibodies (Immunocytochemistry)	Goat anti-Mouse IgG3 Cross-adsorbed Secondary Antibody, Alexa Fluor 488	1:250	Thermo Fisher Scientific Cat# A-21151, RRID: AB_2535784
Secondary antibodies (Immunocytochemistry)	Goat anti-Mouse IgG1 Cross-adsorbed Secondary Antibody, Alexa Fluor 568	1:500	Thermo Fisher Scientific Cat# A-21124, RRID: AB_2535766
Secondary antibodies (Immunocytochemistry)	Goat anti-Mouse IgG2b Cross-adsorbed Secondary Antibody, Alexa Fluor 647	1:250	Thermo Fisher Scientific Cat# A-21242, RRID: AB_2535811
Site-specific nuclease			
Nuclease information	Nuclease type/version	Alt-R Cas9-RNP	
Delivery method	Electroporation	Neon Transfection System (program 6)	
Selection strategy	Single cell cloning + restriction site analysis		
Primers and Oligonucleotides used in this study			
	Target	Forward/Reverse primer (5'-3')	
Correction confirmation (PCR/sequencing)	<i>APP exon 17</i>	GCCCACCCTAATAAC CATTC/TTCAGGATCCCACATCAGAG	
gRNA1 off-target site 1	<i>WNT9B</i>	AATTGGTGGGG ATGGAGGTT/TTCCAAAGTCC TGTTAGTGCCT	
gRNA1 off-target site 2	<i>ATG16L2</i>	CGCCTTCCCTTTCGGT TTG/TGTATTGCCCTGGAGTAAGCC	
gRNA1 off-target site 3	<i>PTPRJ</i>	ACGAGCCAGGCTATTT TTGGA/GCATCGAGACAGCACCGATA	
gRNA1 off-target site 4	<i>XKR6</i>	AGCTTTCITTTCCAGTCG CTGT/CCGAATTATTGCGGTGGCTT	
gRNA1 off-target site 5	<i>RP11-659P15.1</i>	AATTTTGGGAGCCAGGG AGTTT/CTGTCCAGTGATGTGGAGGAAG	
gRNA2 off-target site 1	<i>GPR158</i>	CACTGTAGTCACCATC CTCAGAC/GGATAGAACAGTCACAGACAGAG	
gRNA2 off-target site 2	<i>RP11-246A10.1</i>	TTGGGTGTGAGATACA CTGCTA/GTGTAGTTTGGCCCTTACCC	
gRNA2 off-target site 3	<i>AMFR</i>	CACGTCGTGGGGTAACA TCTG/TGGATTCTTCCAAAAGGACTACC	
gRNA2 off-target site 4	<i>KIAA1598</i>	ATTTGTGTGACTTATTG TCTGGG/TATGTCGTCTGCAAGGTCCC	
gRNA2 off-target site 5	<i>HEATR5A</i>	ACCACAGCTGGCAAGAGA TT/TCAGTGTCTGCTGTGGTATGT	
gRNA1		GGTGTTCITTTGCACaAAGATG	
gRNA2		GTGTTCTTTGCACaAAGATGT	
ssODN		AATTGTAAATTATATTGCAT TTAGAAATTAAAATTCTTT TTCTTAATTTGTTTTCAAGGTGTTCTTTGCAGaAAGACGTCGGTTCAAACAA AGGTGCAATCATTGGAC TCATGGTGGGCGGTGTTGT CATAGCGACAGTGA	




Fig. 1. Generation and characterization of hiPSC lines LUMCi005-A-3, LUMCi005-A-4. Lines are CRISPR-Cas9 edited to correct an autosomal mutation in the amyloid precursor protein (APP) in a dutch-type cerebral amyloid angiopathy (D-CAA) patient line.

England Biolabs) activity and confirmed by Sanger sequencing performed by the Leiden Genome Technology Centre (LGTC). Off-target analysis was performed by PCR amplification and Sanger sequencing of the five most likely off-target sites within coding regions as predicted by CRISPOR (crispor.tefor.net; Fig S1) (Haeussler et al., 2016).

4.2. Immunofluorescence staining

hiPSCs at passage 10 were fixed in 2% PFA for 30 min, permeabilized with 0.1% Triton X-100, and blocked with 4% normal swine serum (NSS, DAKO) at room temperature (RT) for 1 h. Primary antibodies were

added and incubated overnight at 4 °C. After washing, secondary antibodies were added for 1 h at RT (Table 2). Nuclei were stained with DAPI, and coverslips were mounted using Mowiol (Merck Millipore). Images were acquired on a Leica TCS SP8 microscope or the EVOS M7000.

4.3. FACS staining

hiPSCs were dissociated at passage 15 with TrypLE for 5 min at 37 °C. Samples were fixed for 15 min in 200 µl of Reagent A of the fix & perm kit (Thermo Fisher Scientific). The cells were washed once in FACS

buffer (PBS without Ca^{2+} and Mg^{2+} with 0.5% BSA and 2 mM EDTA), resuspended in 80 μl of Reagent B with the conjugated antibodies (Table 2) and incubated in the dark for 60 min at RT. Subsequently, the samples were washed once and resuspended in FACS buffer before being measured on the MACSQuant VYB flow cytometer (Miltenyi Biotec). Analysis was performed using the FlowJotm v.10.6.1.

4.4. *In vitro* trilineage differentiation

The ability of hiPSCs to differentiate into the three germ layers (ectoderm, mesoderm, and endoderm) was assessed using differentiation with the Trilineage differentiation kit (Stem Cell Technologies). The differentiation was done according to the manufacturer's instructions on hESC-qualified Matrigel (Corning) coverslips. After 5 or 7 days of culture cells were fixed using 2 %PFA.

4.5. Karyotype analysis

hiPSCs at passage 9 were karyotyped by Cell Guidance systems (UK) and a total of 20 metaphases were counted.

4.6. Sequencing

Genomic DNA was isolated from hiPSCs using Quick Extract (Lucigen) according to the manufacturer's instructions. The genes of interest were amplified using PlatinumTM Taq DNA Polymerase High Fidelity (Invitrogen) for mutation and off-target analysis using the primers listed in Table 2.

4.7. Mycoplasma test

All lines were tested for the absence of mycoplasma and other human pathogens at passage 35 using the IDEXX BioAnalytics PCR analysis. (Supplementary Material 1).

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Christine L. Mummery is co-founder of Pluriomics bv (now Ncardia bv).

Acknowledgements

We thank N. Nakanishi (National Institute of Advanced Industrial

Science and Technology, Japan) for providing SeV. V. Vermeulen (LUMC) for technical assistance, the Department of Human Genetics, LUMC, for the STR DNA analysis and the Laboratorium voor Diagnostische Genoomanalyse (LGDA), LUMC, for the karyotyping analysis.

This work was supported by The Netherlands Organ-on-Chip Initiative, an NWO Gravitation project funded by the Ministry of Education, Culture and Science of the government of the Netherlands (024.003.001) and the Novo Nordisk Foundation Center for Stem Cell Medicine supported by Novo Nordisk Foundation grants (NNF21CC0073729).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.scr.2023.103180>.

References

- Daoutsali, E., Buijsen, R.A.M., van de Pas, S., Jong, A.'t., Mikkers, H., Brands, T., Eussen, B., de Klein, A., van der Graaf, L.M., Pepers, B.A., Freund, C., Terwindt, G. M., Orlova, V.V., van Roon-Mom, W.M.C., 2019. Generation of 3 human induced pluripotent stem cell lines LUMCi005-A, B and C from a Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch type patient. *Stem Cell Research* 34. <https://doi.org/10.1016/j.scr.2018.101359>.
- Daoutsali, E., Pepers, B.A., Stamatakis, S., van der Graaf, L.M., Terwindt, G.M., Parfitt, D. A., Buijsen, R.A.M., van Roon-Mom, W.M.C., 2023. Amyloid beta accumulations and enhanced neuronal differentiation in cerebral organoids of Dutch-type cerebral amyloid angiopathy patients. *Frontiers in Aging Neuroscience* 14. <https://doi.org/10.3389/fnagi.2022.1048584>.
- Haeussler, M., Schönig, K., Eckert, H., Eschstruth, A., Mianné, J., Renaud, J.-B., Schneider-Maunoury, S., Shkumatava, A., Teboul, L., Kent, J., Joly, J.-S., Concordet, J.-P., 2016. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. *Genome Biology* 17 (1). <https://doi.org/10.1186/s13059-016-1012-2>.
- Herzig, M.C., Winkler, D.T., Burgermeister, P., Pfeifer, M., Kohler, E., Schmidt, S.D., Danner, S., Abramowski, D., Stürchler-Pierrat, C., Bürki, K., van Duinen, S.G., Maat-Schieman, M.L.C., Staufenbiel, M., Mathews, P.M., Jucker, M., 2004. A β is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. *Nature Neuroscience* 7 (9), 954–960.
- Kamp, J.A., Moursel, L.G., Haan, J., Terwindt, G.M., Lesnik Oberstein, S.A.M.J., Van Duinen, S.G., Van Roon-Mom, W.M.C., 2014. Amyloid β in hereditary cerebral hemorrhage with amyloidosis-Dutch type. *Reviews in the Neurosciences* 25, 641–651. <https://doi.org/10.1515/revneuro-2014-0008>.
- Levy, E., Carman, M.D., Fernandez-Madrid, I.J., Power, M.D., Lieberburg, I., van Duinen, S.G., Bots, G.T.A.M., Luyendijk, W., Frangione, B., 1990. Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage. *Dutch Type. Science* 1979 (248), 1124–1126.